Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 7Recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 14INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Renal Insufficiency 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × gallium 68 PSMA-11 × Clear all
NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

NCT07052214 2025-09-10

BiPASS

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
204 enrolled
Genitourinary

Prostatic Neoplasms

NCT05847348 2024-07-03

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
110 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡